Patients with disseminated TB or with CD4 counts less than 200/mm3 were eligible for concurrent initiation of both ART and anti-TB medications back in 2004, whilst those who showed no signs of serious illness had to defer ART until after the initial phase of anti-TB treatment.60 This evidence concerns the gene CD4 and tuberculosis.